EXTRACELLULAR OXYGEN RADICALS AND ISCHEMIC BRAIN INJURY
Project Number5R01NS038944-03
Contact PI/Project LeaderWARNER, DAVID
Awardee OrganizationDUKE UNIVERSITY
Description
Abstract Text
DESCRIPTION: (Verbatim from the Applicant's Abstract) An important mechanism of
ischemic brain damage is production of reactive O2 species, including
superoxide (O2-). Natural defenses against O2- include 3 isozymes of superoxide
dismutase (SOD). CuZnSOD and MnSOD have been shown to be important in
scavenging O2- produced in the intracellular space. The remaining isozyme,
extracellular SOD (EC-SOD), is found only in the extracellular (EC) space.
Transgenic (EC-SOD overexpressing) and knockout (EC-SOD deficient) mice and the
metalloporphyrin compound Mn-TM-2-PyP (and EC-SOD mimetic) provide novel
opportunity to isolate and examine effects of O2- produced in the EC space. We
have shown that EC-SOD overexpression reduces both global and focal ischemic
injury while EC-SOD deficiency increases focal ischemic injury. The goal of
this research is to define mechanisms by which EC-SOD improves ischemic outcome
and determine if these properties can be emulated by use of EC-SOD mimetic
compounds. Our fundamental postulate is that EC-SOD provides a beneficial
effect on ischemic brain by scavenging O2- in the EC space which has been
generated by either activated neutrophils/microglia or membrane bound oxidases.
We will examine whether reperfusion is required for EC-SOD to affect
histologic/behavioral outcome. We will then examine whether EC-SOD deficiency
worsens global ischemic injury and whether this deficiency can be corrected by
administration of Mn-TM-2-PyP. O2- sensitive microelectrodes, OH microdialysis,
and nitrotyrosine assays will be used to determine if manipulation of EC-SOD
expression and use of Mn-TM-2-PyP alters O2- concentrations in ischemic brain.
The source of extracellular O2- will be examined by comparing
histologic/behavioral ischemic outcome in neutrophil depleted EC-SOD
transgenic/knockout mice and whether EC-SOD pharmacologic mimetics have
efficacy in NADPH oxidase knock-out mice lacking respiratory burst activity.
Long-term recovery studies will be performed to assure that neuroprotective
effects of EC-SOD are permanent. Immunoblotting techniques will be used to
determine if EC-SOD expression is upregulated in post-ischemic brain and
whether expressed EC-SOD is intact of cleaved of its heparin binding domain
which might facilitate diffusion to sites of inflammation. We believe this work
will provide important mechanistic insight into how ischemic outcome is
affected by O2- formed in the extracellular space and that this work will
provide novel routes of investigation for therapy of ischemic brain injury.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
07-April-2000
Project End Date
30-June-2003
Budget Start Date
01-February-2002
Budget End Date
30-June-2003
Project Funding Information for 2002
Total Funding
$182,111
Direct Costs
$118,254
Indirect Costs
$63,857
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Neurological Disorders and Stroke
$182,111
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS038944-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS038944-03
Patents
No Patents information available for 5R01NS038944-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS038944-03
Clinical Studies
No Clinical Studies information available for 5R01NS038944-03
News and More
Related News Releases
No news release information available for 5R01NS038944-03
History
No Historical information available for 5R01NS038944-03
Similar Projects
No Similar Projects information available for 5R01NS038944-03